Ortoma’s OTS™ Hip is launched in Japan
To view this Press Release on Ortoma’s website, click here.
Following a clinical evaluation of Ortoma’s OTS™ Hip solution, Ortoma is now working with Johnson & Johnson K.K. to initiate a broad distribution of OTS™ Hip in Japan. OTS™ Hip is a unique solution for AI-assisted orthopedic surgery of hip implants and Johnson & Johnson K.K. has obtained exclusive distribution rights for the Japanese market, for which Ortoma receives an upfront fee.
“For Ortoma, this proves that our product meets the high demands of the strategically important Japanese market. This is a significant milestone for Ortoma and we are confident that our product will create great value for surgeons and be of significant benefit to patients in need of hip replacements.“, comments CEO Linus Byström.
The agreement, signed in December 2021, gives Johnson & Johnson K.K. exclusive distribution rights in Japan of Ortoma Treatment Solution for hip surgery. The agreement included a pilot period where Johnson & Johnson K.K. would evaluate the products clinically before introducing it in the Japanese market. The evaluation was conducted after Ortoma obtained the necessary regulatory approvals for the OTS™-products. The pilot period ended with good results and Ortoma receives a one-time fee for the exclusive distribution rights of OTS™ Hip in Japan. Ortoma is now working with Johnson & Johnson K.K. to initiate a broad distribution of OTS™ Hip in Japan.
About Ortoma AB (publ)
Ortoma AB develops surgical systems for the planning and positioning of implants in hip, knee and spinal surgery. The purpose of the company’s surgical system, Ortoma Treatment Solution™ (OTS) is to enable surgeons to accurately measure and plan 3D surgery for the placement of joint implants, and during surgery, to optimally position the implant in the patient. Ortoma’s surgical system is aimed at providing better patient outcomes, fewer complications and less follow-up surgeries – and thus better long-term survival rates for implants. OTS is a system that is easily integrated into the processes and routines currently used in surgery, thereby increasing efficiency. Globally, more than 7.5 million orthopedic procedures are performed each year where OTS could be used in hip, knee and spinal surgery. In Sweden, around 42,000 surgical procedures were performed last year, involving hip, knee or spinal surgery. Ortoma’s B shares are listed on Spotlight Stock Market.
To view this Press Release on Ortoma’s website, click here.
